The three-dimension preclinical models for ferroptosis monitoring

Yiming Meng 1,*, Jing Sun 2, Guirong Zhang 1, Tao Yu 3,4,* and Haozhe Piao 1,4,*

1Department of Central Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, 2Department of Biobank, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, 3Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, 4Department of Neurosurgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China

As a new programmed cell death process, ferroptosis has shown great potential and uniqueness in experimental and treatment-resistant cancer models. Currently, the main tools for drug research targeting ferroptosis are tumor cells cultured in vitro and tumor models established in rodents. In contrast, increasing evidence indicates that reactivity may differ from modifications in mice or humans in the process of drug screening. With the blossoming of 3D culture technology, tumor organoid culture technology has gradually been utilized. Compared with traditional 2D culture and tumor tissue xenotransplantation, tumor organoids have a significantly higher success rate. They can be cultured quickly and at a lower cost, which is convenient for gene modification and large-scale drug screening. Thus, combining 3D cell culture technology, drug monitoring, and ferroptosis analysis is necessary to develop the impact of ferroptosis-related agents in tumor treatment.

KEYWORDS
ferroptosis, 3D cell culture, anti-tumor therapy, drug, assay

Introduction

Although modern medicine has made remarkable progress in treating malignant tumors, malignant tumors are still the number one killer of human death. There is still a great demand for developing new anti-tumor drugs (M. Wu et al., 2022). However, most medicines fail to achieve their application from the laboratory to the clinic. Presently, the global screening technology of drug efficacy is mainly based on pharmacodynamic models (Mai et al., 2022). Cell models are one of the drug screening models. In recent years, more additional cell models have been developed for drug screening with the development of cell biology (de Almeida et al., 2022). The effects of the candidate drug on cell activity, apoptosis, migration, differentiation, metabolism, and other behaviors can be examined at the cellular level. The response speed of cell experiments is breakneck, and the efficacy and toxicity of drug candidates can be analyzed in a short period. However, the traditional cell models usually use two-dimensional (2D) cells cultured in a plane whose morphological
structure and physiological microenvironment are very different from those in the human body and cannot simulate the in vivo situation well (Calpe and Kovacs 2020).

On the other hand, 2D cell models are more sensitive to drug responses due to the lack of intercellular junctions and extracellular matrix, which are prone to provide false-positive data for drug screening. Therefore, more scientific research institutions and drug development companies have begun using three-dimensional (3D) cells as a drug screening model. 3D cells have more similar in vivo morphological structure, drug response, gene expression, drug sensitivity, and more robust drug tolerance (Castro et al., 2021). 3D cells have shown great potential as a cell model for next-generation drug screening, which takes into account the advantages of traditional cell models in terms of high throughput, low cost, high efficiency, and animal models closer to the in vivo situation. Although drug screening based on 3D cells is still in its infancy, its excellent physiological properties make drug screening based on 3D cell models have broad application prospects (Castro et al., 2021; Pamarthy and Sabawy 2021). Ferroptosis-related agents are rapidly evolving in developing new drugs and are particularly effective in inhibiting several types of cancer (Fuhrmann and Brune 2022). Ferroptosis is an iron-dependent cell death mode that differs from traditional programmed cell death, such as apoptosis, pyroptosis, and autophagy (Zhang and Liu 2022). It is illustrated by the accumulation of lipid peroxides induced by reactive oxygen species. The main manifestations of ferroptosis are marked mitochondrial shrinkage, increased double-membrane density, reduction or disappearance of mitochondrial cristae but intact cell membrane, standard size of nucleus, and uncondensed chromatin (Stockwell 2022). The core mechanism of ferroptosis is the depletion of the antioxidant peptide glutathione (GSH) in cells by inhibiting the cystine-glutamate anti-transporter, eventually accumulating lethal levels of lipid peroxides (Grube et al., 2022). Unlike programmed cell death, ferroptosis is a regulated cell death that relies on specific molecular mechanisms, so specific drugs and genetic interventions can be exploited to speed up or slow down the ferroptosis process (Figure 1).

Ferroptosis-inducing agents could enhance the antitumor effects of radiotherapy, and ferroptosis inhibitors also alleviate radiotherapy-induced lung injury, pulmonary fibrosis, and myeloid radiation sickness. Therefore, modulating the ferroptosis pathway to obtain the most significant clinical
benefit in tumor therapy is a vital issue worthy of further study. (Chin et al., 2022; Peng et al., 2022). In Investigative Dermatology, Wang et al. (S. Wang, et al., 2022) identify the Calcium/Calmodulin Dependent Protein Kinase 2 (CAMKK2)-adenosine monophosphate-activated protein kinase-nuclear factor erythroid2-related factor 2 (NRF2) signaling axis is a negative regulator of ferroptosis and show that inhibition of CAMKK2 improves anti-PD-1 therapy effect. These results provide new opportunities to develop ferroptosis-inducing therapies in combination with immune checkpoint drugs. Recent research supports using 3D culture models to identify therapeutic targets that traditional 2D assays may obscure. They believe that cells’ antioxidant capacity is a new strategy for cancer treatment. Importantly, they observed differences in the sensitivity of inner and outer cells to ferroptosis, suggesting that different tumor regions may have various capacities for oxidative stress and sensitivity to ferroptosis-inducing compounds (Takahashi et al., 2020). Thus, combining 3D cell culture technology, drug monitoring, and ferroptosis analysis is necessary to develop the impact of ferroptosis-related agents in tumor treatment.

**Ferroptosis in the 3D cell culture**

Targeting multiple oxidative stress defense programs may be necessary to maximize the killing of all cells in the tumor. So, the therapeutic strategies may be by targeting NRF2 (an oxidative defense transcription factor) (Panieri et al., 2022), directly targeting glutathione peroxidase 4 (GPX4), targeting NRF2 transcriptional targets that affect ferroptosis (e.g., Solute Carrier Family 7 Member 11), or targeting other pathways that affect sensitivity to lipid peroxidation (e.g., Acyl-CoA Synthetase Long-Chain Family Member 4) by pooled CRISPR-Cas9 Screen in 3D culture (Takahashi et al., 2020). For the 3D culture, the cells were plated on Matrigel-coated 96 black well plates in complete media supplemented with 2% Matrigel and 1 μg/ml doxycycline. The spheroid cells were re-fed with fresh media every two or 3 days and fixed with 4% paraformaldehyde at the endpoint. The benefit of the spheroid model allowed us to reveal that high NRF2 activity is required for lung cancer spheroid formation and that loss of NRF2 has dramatic effects on two distinct processes during spheroid formation: proliferation and survival of spheroid cells. They exemplified how NRF2 is a connection between cancer cell architecture and ferroptosis; they notify that NRF2 hyperactivation improves 3D proliferation of non-small cell lung cancer (NSCLC), partly through quelling ferroptosis in the extracellular matrix (ECM)-deprived, inner cells of cancer spheroids. Their study provides a basis for further investigation of the link between the antioxidant response of ferroptosis and the extracellular matrix of the tumor microenvironment (W.L. Wu and Papagiannakopoulos 2020). Developing compounds that target anti-ferroptosis modulators could be a promising approach and particularly effective in tumor combination therapy (Kurt-Celep et al., 2022; Y. Wang, et al., 2022).

**Quantitatively determine ferroptosis in spheroids**

In numerous large-scale unexplored drug trials in 2008, the single-layer planar culture model was not enough to predict the actual situation of drugs in tumor tissues, and the experimental results were rarely consistent with clinical trial consequences (Mohr et al., 2022). With the continuous development of cell culture media such as scaffolds, gels, and other matrices and support materials, 3D tumor cell models can simulate in vitro a 3D space and microenvironment similar to in vivo. This technique has gradually become the most promising cell research model. 3D cultures, including spheroids, are nowadays recognized as a better model of the in vivo environment, whereas rare detailed cell death (including ferroptosis) assays are available for 3D cultures (Jung et al., 2022; Yan et al., 2022). Robin Demuynck’s (Demuynck et al., 2020) employed 3D cells culture technology to demonstrate an assay that can effectively identify diverse types of cell death, including ferroptosis, and quantitatively assess cell death in tumor spheroids, the 3D Cell Death Assay (3DELTA). Their method used Sytox dye, intercalated with DNA, as a cell death marker and Triton X-100, which efficiently penetrated all cells in the spheroid, to determine 100% cell death. Spheroids were formed by seeding cells (L929sAhFasmouse fibrosarcoma cells and SK-OV-3-Luc-GFP human ovarian cancer cells) on agarose microwell chips—the chip made by pouring liquid agarose onto a polydimethylsiloxane (PDMS) mold. The cells will form clusters, leading to the formation of spheroids. Sytox dyes intercalate with DNA with a high affinity. Sytox Green is non-luminescent outside viable cells. When cells permeabilize at the end of the cell death process, the plasma membrane is ruptured, and Sytox Green will bind to DNA and fluoresce green. Moreover, it emits green fluorescence, which can then be measured.

The following formula calculated the percentage of the cell death:

\[
\text{average}_{\text{stain}} \left[ \text{ML162} \right] - \frac{\text{average}_{\text{stain}} \left[ \text{background} \right]}{\text{average}_{\text{stain}} \left[ \text{Triton X-100} \right] - \text{average}_{\text{stain}} \left[ \text{background} \right]} \times 100\%
\]

Cell ferroptosis induced with 5 μM ML-162. Spheroids stained with Sytox Green (1.929) or Sytox Blue (SKOV) and cell death, an increase in fluorescence intensity, was measured 24 h later with a Tecan Spark microplate reader. Afterward, the spheroids permeabilized with Triton X-100 0.05% (v/v). Fluorescence intensity was measured and taken as 100% cell death. After optimization of Sytox concentration, Triton X-100 concentration, and time, it demonstrated that the 3D cell death assay (3DELTA) method could detect the signal of all cells
without disintegrating the spheroids. Sytox fluorescence intensities were detected by the Tecan Spark™ 20 M microplate multimode reader. In this work, they have shown that this approach, can identify efficiently and quantify different types of cell death, including ferroptosis in tumor spheroids. 3D ELTA will enable the study of high-throughput cell death responses of tumor spheroids to therapy. Several issues arose during this study, including higher intensity of Sytox in stimulated cells compared to Triton X-100, resulting in >100% cell death; incomplete trypsinization of D10 spheroids; When plated, the spheroids disintegrated after 1 day during the ferroptosis assay; results were overestimated due to, for example, high intensity. Ways to solve the problem include more vigorous resuspension cells for 1 h; having an incubation step with collagenase I instead of trypsin; operating a suspension plate instead of an adherent plate to prevent cells from sticking to the plate; utilizing lower gains to optimize gain settings for new cell lines. The assay and 3D model results will be more clinically representative of the therapeutic response and improve the success rate of translating drugs into clinical trials.

Discussion

The research on ferroptosis is in the ascendant, and many mechanisms are not yet precise. However, it can be considered a regulated cell death process mainly due to the damage to the intracellular redox protection system and the destruction of the membrane structure caused by the imbalance of iron homeostasis (Qu et al., 2022). Ferroptosis is a double-edged sword. On the one hand, it can eliminate pathological or infected cells to maintain the body’s homeostasis and continuity. On the other hand, it may damage normal cells and cause disease. Induction of exogenous stimuli and substances that promote or prevent ferroptosis play different roles in different pathological conditions (Chen et al., 2021; Koren and Fuchs 2021). As a unique programmed cell death process, ferroptosis has shown great potential and uniqueness in experimental and treatment-resistant cancer models. Therefore, the US Food and Drug Administration has approved octamine, sorafenib, and silica nanoparticles as ferroptosis inducers to treat tumors (Zhu et al., 2022).

The induction of ferroptosis in tumor cells is one of the emerging anti-tumor therapeutic strategies, and its related ferroptosis-inducing drugs have been applied in clinical tumor treatment. Although it has brought prospects for tumor patients, numerous problems still have not yet been solved. The research on tumor ferroptosis also requires to be carried out from the perspective of the intrinsic characteristics of tumors (Del Valle et al., 2020; Su et al., 2020). Various aspects of the tumor microenvironment have been involved in ferroptosis, such as inflammation, immunity, stromal cells, angiogenesis, and metabolism. As described above (Takahashi et al., 2020), they encountered that 2D culture conditions display little sensitivity to NRF2 knockdown, while the expansion of cells carrying NRF2-activating mutations is dramatically impaired in 3D culture. Under 3D spheroid growth conditions, spheroid cores deprived of extracellular matrix undergo higher reactive oxygen species (ROS), lipid peroxidation, ferroptosis, and central scavenging. NRF2 activation facilitates 3D growth by interfering with ferroptosis and increasing core survival. In the future, ferroptosis can be linked to the tumor microenvironment, and further study the effects of various factors in the tumor microenvironment on ferroptosis. These findings provide several insights into tumor therapy (H. Wang et al., 2021). At present, some factors affecting ferroptosis in the tumor microenvironment have been unearthed. Screening or synthesizing drugs with synergistic effects in combination with ferroptosis-inducing drugs by 3D culture methods is a prospective way to explore anti-tumor drugs. The synergistic ferroptosis medicines may improve the prognosis of tumor patients by accelerating the ferroptosis of tumor cells and increasing the efficacy of ferroptosis-inducing drugs in clinical anti-tumor therapy. The in-depth research on the effect of the tumor microenvironment on ferroptosis by the 3D culture method will open a new chapter in anti-tumor treatment.

Author contributions

HP, TY, and YM wrote the manuscript; JS and GZ collected the related articles. All authors helped with reviewing the article.

Funding

This research work is supported by the Fundamental Research Funds for the Central Universities, Natural Science Foundation (20180550488 and 2020-ZLLH-38 to YM) of Liaoning Province, Young and middle-aged technological innovation talents in Shenyang of YM (RC200491), and Excellent Talent Fund of Liaoning Province Cancer Hospital of YM.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

Calpe, B., and Kovacs, W. J. (2020). High-throughput screening in multicellular spheroids for drug discovery in the tumor microenvironment. *Expert Opin. Drug Discov.* 15 (8), 955–967. doi:10.1080/17464441.2020.1750769

Castro, F., Leite Pereira, C., Helena Macedo, M., Almeida, A., Jose Silveira, M., Dias, S., et al. (2023). Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening. *Adv. Drug Deliv. Rev.* 175, 113824. doi:10.1016/j.addr.2022.113824

Chen, X., Kang, R., Kroemer, G., and Tang, D. (2021). Targeting ferropoticosis in pancreatic cancer: A double-edged sword. *Trends Cancer* 7 (10), 891–901. doi:10.1016/j.trecan.2021.04.005

Chen, Y. C., Yang, L. X., Hsu, F. T., Hsu, C. W., Chang, T. W., Chen, H. Y., et al. (2022). Iron oxide-Chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy initiated ferropoticosis and immunostimulation. *J. Nanobiotechnology* 20 (1), 373. doi:10.1186/s12951-022-01575-7

de Almeida, L. G. N., Thode, H., Elsambolchi, Y., Chopra, S., Young, D., Gill, S., et al. (2022). Matrix metalloproteinases: From molecular mechanisms to physiology, pathophysiology, and pharmacology. *Pharmacol. Rev.* 74 (3), 712–768. doi:10.1124/pr.121.001349

Del Valle, A. C., Yeh, C. K., and Huang, Y. F. (2020). Near infrared-activatable platinum-decorated gold nanostars for synergistic photothermal/ferropoticosis therapy in combating cancer drug resistance. *Adv. Healthc. Mater.* 9 (9), 26500864. doi:10.1002/adhm.202000864

Demuyrinck, R., Efimova, I., Lin, A., Declercq, H., and Krysko, D. V. (2020). A 3D cell death assay to quantitatively determine ferropoticosis in spheroids. *Cells* 9 (3), 703. doi:10.3390/cells9030703

Fuhrmann, D. C., and Brune, B. (2022). A graphical journey through iron metabolism, microRNAs, and hypoxia in ferropoticosis. *Redox Biol.* 54, 102365. doi:10.1016/j.redox.2022.102365

Grube, J., Weitsch, M. M., Mohs, A., Erschfeld, S., Lynen, C., Trautwein, C., et al. (2022). ACSL4-dependent ferropoticosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression. *Cell Death Dis.* 13 (8), 704. doi:10.1038/s41419-022-05137-5

Jung, M., Ghamrawi, S., Du, E. Y., Gooding, J. J., and Kavallaris, M. (2022). Advances in 3D bioprinting for cancer biology and precision medicine: From matrix design to application. *Adv. Healthc. Mater.* 2022, 121704. doi:10.1002/adhm.2022121704

Koren, E., and Fuchs, Y. (2021). Modes of regulated cell death in cancer. *Cancer Discov.* 11 (2), 245–265. doi:10.1158/2159-8290.CD-20-0789

Kurt-Celep, I., Zhleva Dimitrova, D., Gerevova, R., Uba, A. J., Zengin, G., Yildizrugay, E., et al. (2022). An in-depth study on the metabolite profile and biological properties of primula auriculata extracts: A fascinating sparkle on the way from nature to functional applications. *Antioxidants (Basel)* 11 (7), 1377. doi:10.3390/antiox11071377

Mai, C. W., Chin, K. Y., Foong, L. C., Pang, K. L., Yu, B., Shu, Y., et al. (2022). Matrix metalloproteinases: From molecular mechanisms to functional applications. *Front. Immunol.* 13, 920059. doi:10.3389/fimmu.2022.920059

Mohr, E., Thum, T., and Bar, C. (2022). Accelerating cardiovascular research: Recent advances in translational 2D and 3D heart models. *Eur. J. Heart Fail.* doi:10.1002/ejhf.2831

Pamarrthy, S., and Sabhaswy, H. E. (2021). Patient derived organoids in prostate cancer: Improving therapeutic efficacy in precision medicine. *Mol. Cancer* 20 (1), 125. doi:10.1186/s12943-021-01426-5

Paneri, E., Pinho, S. A., Alfonso, G. J. M., Oliveira, P. J., Cunha-Oliveira, T., and Sasso, L. (2022). NRF2 and mitochondrial function in cancer and cancer stem cells. *Cells* 11 (15), 2401. doi:10.3390/cells11152401

Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., et al. (2022). Regulated cell death (RCD) in cancer: Key pathways and targeted therapies. *Signal Transduct. Target. Ther.* 7 (1), 286. doi:10.1038/s41392-022-01110-y

Qu, C., Peng, Y., and Liu, S. (2022). Ferropoticosis biology and implication in cancers. *Front. Mol. Biosci.* 9, 892957. doi:10.3389/fmolb.2022.892957

Stockwell, B. R. (2022). Ferropoticosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. *Cell* 185 (14), 2401–2421. doi:10.1016/j.cell.2022.06.003

Su, Y., Zhao, R., Zhou, L., Zhang, Z., Shen, Y., Lv, H., et al. (2020). Ferropoticosis, a novel pharmacological mechanism of anti-cancer drugs. *Cancer Lett.* 483, 127–136. doi:10.1016/j.canlet.2020.02.015

Takahashi, N., Cho, P., Selfors, I. M., Kuiken, H. J., Kaul, R., Fujisawa, T., et al. (2020). 3D culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and ferropoticosis. *Mol. Cell* 80 (5), 828–844.e6. doi:10.1016/j.molcel.2020.10.010

Wang, H., Cheng, Y., Mao, C., Liu, S., Xiao, D., Huang, J., et al. (2021). Emerging mechanisms and targeted therapy of ferropoticosis in cancer. *Mol. Ther.* 29 (7), 2185–2208. doi:10.1016/j.ymthe.2021.03.022

Wang, S., Yi, X., Wu, Z., Sun, S., Dai, W., Wang, H., et al. (2022). CAMKK2 defines ferropoticosis sensitivity of melanoma cells by regulating AMPK/NRF2 pathway. *J. Invest. Dermatol.* 142 (1), 189–200.e8. doi:10.1111/jid.2021.05.025

Wang, Y., Tang, B., Zhu, J., Yu, J., Hui, J., Xia, S., et al. (2022). Emerging mechanisms and targeted therapy of ferropoticosis in neurological diseases and neuro-oncology. *Int. J. Biol. Sci.* 18 (10), 4260–4274. doi:10.7150/ijbs.27251

Wu, M., Wang, M., Jia, H., and Wu, P. (2022). Extracellular vesicles: Emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy. *Drug Deliv. (Lond.)* 29 (1), 2513–2538. doi:10.1080/17519522.2022.2104404

Wu, W. L., and Papagiannakopoulou, T. (2020). The center cannot hold: NRF2 battles ferropoticosis in the 3rd dimension. *Mol. Cell* 80 (5), 760–761. doi:10.1016/j.molcel.2020.11.022

Yan, J., Li, Z., Guo, J., Liu, S., and Guo, J. (2022). Organ-on-a-chip: A new tool for in vitro research. *Biosens. Bioelectron.* X. 216, 114626. doi:10.1016/j.biox.2022.114626

Zhang, C., and Liu, N. (2022). Ferropoticosis, necroptoticosis, and pyroptoticosis in the occurrence and development of ovarian cancer. *Front. Immunol.* 13, 920059. doi:10.3389/fimmu.2022.920059

Zhu, J., Wang, X., Su, Y., Shao, J., Song, X., Wang, W., et al. (2022). Multifunctional nanolocks with GSH as the key for synergistic ferropoticosis and anti-chemotherapeutic resistance. *Biomaterials* 2022, 121704. doi:10.1016/j.biomaterials.2022.121704